ADVAXIS, INC. You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year endedDecember 31, 2021 (the "Annual Report"), our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Overview We are a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. Our current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway using gamma secretase inhibitors. Gamma secretase is the enzyme responsible for Notch activation and, when inhibited, turns off the Notch pathway activation. Aberrant activation of the Notch pathway has long been implicated in multiple solid tumor and hematological cancers and has often been associated with more aggressive cancers. In cancers, Notch is known to serve as a critical facilitator in processes such as cellular proliferation, survival, migration, invasion, drug resistance and metastatic spread, all of which contribute to a poorer patient prognosis. AL101 and AL102 are designed to address the underlying key drivers of tumor growth, and our initial Phase 2 clinical data of AL101 suggest that our approach may address shortcomings of existing treatment options. We believe that our novel product candidates, if approved, have the potential to transform treatment outcomes for patients suffering from rare and aggressive cancers. Our product candidates, AL101 and AL102, are being developed as potent, selective, small molecule gamma secretase inhibitors, or GSIs. We obtained an exclusive, worldwide license to develop and commercialize AL101 and AL102 from Bristol-Myers Squibb Company, or BMS, inNovember 2017 . BMS evaluated AL101 in three Phase 1 studies involving more than 200 total subjects and AL102 in a single Phase 1 study involving 36 subjects with various cancers who had not been prospectively characterized for Notch activation, and to whom we refer to as unselected subjects. While these Phase 1 studies did not report statistically significant overall results, clinical activity was observed across these studies in cancers in which Notch has been implicated as a tumorigenic driver. We are currently evaluating AL102, our oral GSI for the treatment of desmoid tumors, in our RINGSIDE Phase 2/3 pivotal study. InFebruary 2022 , Part A completed enrollment of 42 patients with progressive desmoid tumors in three study arms across three doses of AL102. We reported initial interim data from Part A inJuly 2022 with additional data expected to be released at a medical conference. in the third quarter of 2022. Part B of the study will be a double-blind placebo-controlled study enrolling up to 156 patients with progressive disease, randomized between AL102 or placebo. The study's primary endpoint will be progression free survival, or PFS with secondary endpoints including ORR, duration of response, or DOR and patient reported QOL measures. In addition, we collaborated withNovartis International Pharmaceutical Limited , or Novartis, to develop AL102 for the treatment of multiple myeloma, or MM, in combination with Novartis' B-cell maturation antigen, or BCMA, targeting therapies. OnJune 2, 2022 , Novartis informed the Company that Novartis does not intend to exercise its option to obtain an exclusive license for AL102, thereby terminating the agreement. We are currently concluding a Phase 2 ACCURACY trial for the treatment of recurrent/metastatic adenoid cystic carcinoma, or R/M ACC, in subjects with progressive disease and Notch-activating mutations. We refer to this trial as the ACCURACY trial. We use next-generation sequencing, or NGS, to identify patients with Notch-activating mutations, an approach that we believe will enable us to target the patient population with cancers that we believe are most likely to respond to and benefit from AL101 treatment. We chose to initially target R/M ACC based on our differentiated approach, which is comprised of: data generated in a Phase 1 study of AL101 in unselected, heavily pretreated subjects conducted by BMS, our own data generated in patient-derived xenograft models, our bioinformatics platform and our expertise in the Notch pathway. If approved, we believe that AL101 has the potential to be the first therapy approved by the FDA for patients with R/M ACC and address the unmet medical need of these patients. AL101 was granted Orphan Drug Designation inMay 2019 for the treatment of adenoid cystic carcinoma, or ACC, and fast track designation inFebruary 2020 for the treatment of R/M ACC. We reported interim data regarding the most recent safety efficacy, pharmacokinetics, and pharmacodynamics data from Phase 2 of the ACCURACY trial inJune 2022 . We are also developing AL102 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia. Based on findings from our Phase 1 study of AL101 and supporting data from our preclinical studies, we intend to commence a Phase 2 clinical trial of AL102 for the treatment of R/R T-ALL around year end of 2022, subject to the impact of COVID-19 on our business. 12
As part of our efforts to focus our resources on the more advanced programs and studies including the RINGSIDE study in desmoid tumors and the ACCURACY study for ACC, we elected to discontinue the TENACITY trial, which was evaluating AL101 as a monotherapy in an open-label Phase 2 clinical trial for the treatment of patients with Notch-activated R/M TNBC. We were incorporated as aDelaware corporation onNovember 14, 2017 , and our headquarters is located inRehovot, Israel . Our operations to date have been limited to organizing and staffing our company, business planning, raising capital and conducting research and development activities for our product candidates. To date, we have funded our operations primarily through the sales of common stock and convertible preferred stock. We have incurred significant net operating losses in every year since our inception and expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. Our net losses were approximately$8.1 million and$18.2 million for the three and six months endedJune 30, 2022 , respectively. As six months endedJune 30, 2022 , we had an accumulated deficit of$129.4 million . We anticipate that our expenses will increase as we: ? advance our development of AL101 for the treatment of R/M ACC;
? advance our Phase 2/3 RINGSIDE pivotal trial of AL102 for the treatment of
desmoid tumors, or obtain and conduct clinical trials for any other
product candidates;
? assuming successful completion of our Phase 2 ACCURACY trial of AL101 for
the treatment of R/M ACC, may be required by the FDA to complete Phase 3
clinical trials to support submission of a New Drug Application, or NDA,
of AL101 for the treatment of R/M ACC;
? establish a sales, marketing and distribution infrastructure tocommercialize AL101 and/or AL102, if approved, and for any other product
candidates for which we may obtain marketing approval;
? maintain, expand, protect and enforce our intellectual property portfolio;
? hire additional staff, including clinical, scientific, technical,
regulatory operational, financial, commercial and other personnel, to
execute our business plan; and
? add clinical, scientific, operational, financial and managementinformation systems and personnel to support our product development and
potential future commercialization efforts, and to enable us to operate as
a public company.
We do not expect to generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate. Additionally, we currently use contract research organizations, or CROs, to carry out our clinical development activities. Furthermore, we incur additional costs associated with operating as a public company. As a result, we will need substantial additional funding to support our continuing operations, pursue our growth strategy and continue as a going concern. Until such time as we can generate significant revenue from product sales, if ever, we expect to fund our operations through public or equity offerings or debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our current or any future product candidates. Because of the numerous risks and uncertainties associated with therapeutics product development, we are unable to predict accurately the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. As ofJune 30, 2022 , we had cash and cash equivalents of approximately$20.1 million . Due to the uncertainty in securing additional funding, and the insufficient amount of cash and cash equivalent resources atDecember 31, 2021 , we have concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date of the filing of this Quarterly Report on Form 10-Q. See "- Liquidity and Capital Resources." Substantial doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock, and it may be more difficult for us to obtain financing. If potential collaborators decline to do business with us or potential investors decline to participate in any future financings due to such concerns, our ability to increase our cash position may be limited. We will need to generate significant revenues to achieve profitability, and we may never do so. Because of the numerous risks and uncertainties associated with the development of our current and any future product candidates, the development of our platform and technology and because the extent to which we may enter into collaborations with third parties for development of any of our product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses required for completing the research and development of our product candidates. 13 If we raise additional funds through marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate product candidate development programs or future commercialization efforts, grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves or discontinue operations.
Bristol-Myers Squibb License Agreements
InNovember 2017 , we entered into an exclusive worldwide license agreement with Bristol-Myers Squibb Company, or BMS, for AL101 and AL102, each a small molecule gamma secretase inhibitor in development for the treatment of cancers. Under the terms of the license agreement, we have licensed the exclusive worldwide development and commercialization rights for AL101 (previously known as BMS-906024) and AL102 (previously known as BMS-986115). We are responsible for all future development and commercialization of AL101 and AL102. In consideration for the rights granted under the agreement, we paid BMS a payment of$6 million and issued to BMS 1,125,929 shares of Series A preferred stock valued at approximately$7.3 million , which converted to 562,964 shares of common stock in connection with our initial public offering, or IPO. We are obligated to pay BMS up to approximately$142 million in the aggregate upon the achievement of certain clinical development or regulatory milestones and up to$50 million in the aggregate upon the achievement of certain commercial milestones by each product containing the licensed BMS compounds. In addition, we are obligated to pay BMS tiered royalties ranging from a high single-digit to a low teen percentage on worldwide net sales of all products containing the licensed BMS compounds. BMS has the right to terminate the BMS License Agreement in its entirety upon written notice to us (a) for insolvency-related events involving us, (b) for our material breach of the BMS License Agreement if such breach remains uncured for a defined period of time, (c) for our failure to fulfill our obligations to develop or commercialize the BMS Licensed Compounds and/or BMS Licensed Products not remedied within a defined period of time following written notice by BMS, or (d) if we or our affiliates commence any action challenging the validity, scope, enforceability or patentability of any of the licensed patent rights. We have the right to terminate the BMS License Agreement (a) for convenience upon prior written notice to BMS, the length of notice dependent on whether a BMS Licensed Product has received regulatory approval, (b) upon immediate written notice to BMS for insolvency-related events involving BMS, (c) for BMS's material breach of the BMS License Agreement if such breach remains uncured for a defined period of time, or (d) on a BMS Licensed Compound-by-BMS Licensed Compound and/or BMS Licensed Product-by-BMS Licensed Product basis upon immediate written notice to BMS if we reasonably determine that there are unexpected safety and public health issues relating to the applicable BMS Licensed Compounds and/or BMS Licensed Products. Upon termination of the BMS License Agreement in its entirety by us for convenience or by BMS, we grant an exclusive, non-transferable, sublicensable, worldwide license to BMS under certain of our patent rights that are necessary to develop, manufacture or commercialize BMS Licensed Compounds or BMS Licensed Products. In exchange for such license, BMS must pay us a low single-digit percentage royalty on net sales of the BMS Licensed Compounds and/or BMS Licensed Products by it or its affiliates, licensees or sublicensees, provided that the termination occurred after a specified developmental milestone for such BMS Licensed Compounds and/or BMS Licensed Products. Novartis License Agreements InDecember 2018 , we entered into an evaluation, option and license agreement, or the Novartis Agreement, withNovartis International Pharmaceutical Limited , or Novartis, pursuant to which we granted Novartis an exclusive option to obtain an exclusive license to research, develop, commercialize and manufacture AL102 for the treatment of multiple myeloma. We supplied Novartis quantities of AL102, products containing AL102 and certain other materials for purposes of conducting evaluation studies not comprising human clinical trials during the option period, together with our know-how as may have been reasonably be necessary in order for Novartis to conduct such evaluation studies. Novartis agreed to reimburse us for all such expenses. At any time during the option term, Novartis may have exercised its option by payment of a low eight figure option exercise fee. If Novartis exercised its option, it would have been obligated to pay us up to an additional$245 million upon the achievement of certain clinical development and commercial milestones. In addition, Novartis was obligated to pay us tiered royalties at percentages ranging from a mid-single digit to a low double-digit percentage on worldwide net sales of products licensed under the agreement.
On
14
Financial Overview
Except as described below, there have been no material changes from the
disclosure provided under the caption "Components of Results of Operations" in
our Annual Report on Form 10-K for the year ended
Results of Operations
Comparison of the three and six months ended
The following table summarizes our results of operations for the three and six
months ended
For the Three Months For the Six Months
Ended Ended
June 30, June 30,
2022 2021 2022 2021
($ in thousands, except share and per share amounts)
(Unaudited)Revenues from licensing agreement $ 38$ 761
$ 496 $ 1,735 Cost of services (38 ) (761 ) (406 ) (1,735 ) Gross profit - - 90 - Operating expenses: Research and development 5,580 8,121 13,083 15,046
General and administrative 2,260 2,536 4,701 4,839 Operating loss (7,840 ) (10,657 ) (17,694 ) (19,885 ) Financial Income (Loss), net (156 ) (22
) (140 ) (114 ) Loss before income tax (7,996 ) (10,679 ) (17,834 ) (19,999 ) Taxes on income (214 ) (162 ) (403 ) (410 ) Net loss (8,210 ) (10,841 ) (18,237 ) (20,409 ) Net Loss per share attributable to common stockholders, basic and diluted$ (0.54 ) $ (0.75 ) $ (1.19 ) $ (1.46 ) Weighted average common shares outstanding, basic and diluted 15,312,766 14,417,423
15,306,823 13,954,676
Revenue
To date, we have not generated any revenue from product sales and we do not
expect to generate any revenue from the sale of products in the foreseeable
future. If our development efforts for our product candidates are successful and
result in regulatory approval and successful commercialization efforts, we may
generate revenue from product sales in the future. We cannot predict if, when,
or to what extent we will generate revenue from the commercialization and sale
of our product candidates. We may never succeed in obtaining regulatory approval
for any of our product candidates.
For the three months ended June 30, 2022 and 2021, we recognized approximately
$38 thousand and $0.8 million in revenue, respectively. For the six months ended
of June 30, 2022 and 2021, we recognized approximately $0.5 million and $1.7
million in revenue, respectively, mainly as a result of the Novartis Agreement.
Refer to Note 2 to our unaudited condensed consolidated financial statements for
information regarding our recognition of revenue under the Novartis Agreement.
Research and Development
Research and development expenses consist primarily of costs incurred for our research activities, including the development of and pursuit of regulatory approval of our lead product candidates, AL101 and AL102, which include:
? employee-related expenses, including salaries, benefits and stock-based
compensation expense for personnel engaged in research and development
functions;
? expenses incurred in connection with the preclinical and clinical
development of our product candidates, including under agreements with
CROs, investigative sites and consultants;
? costs of manufacturing our product candidates for use in our preclinical
studies and clinical trials, as well as manufacturers that provide
components of our product candidates for use in our preclinical and
current and potential future clinical trials;
? costs associated with our bioinformatics platform;
? consulting and professional fees related to research and development
activities;
? costs related to compliance with clinical regulatory requirements; and
? Facility costs and other allocated expenses, which include expenses for
rent and maintenance of our facility, utilities, depreciation and other
supplies.
15
We expense research and development costs as incurred. Our external research and
development expenses consist primarily of costs such as fees paid to
consultants, contractors and CROs in connection with our preclinical and
clinical development activities. We typically use our employee and
infrastructure resources across our development programs and we do not allocate
personnel costs and other internal costs to specific product candidates or
development programs with the exception of the costs to manufacture our product
candidates.
Three Months Ended June 30, Six Months Ended June 30,
$ % $ %
2022 2021 Change Change 2022 2021 Change Change
($ in thousands)
(Unaudited)
Research and Development 5,580 8,121 (2,541 ) (31 )% 13,083 15,046 (1,963 ) (13 )%
Research and development expenses were approximately $5.6 million for the three
months ended June 30, 2022 , compared to approximately $8.1 million for the three
months ended June 30, 2021 , a decrease of approximately $2.5 million . The
decrease was due to winding down of the ACCURACY trial. Research and development
expenses were approximately $13.1 million for the six months ended June 30, 2022
compared to approximately $15.0 million for the six months ended June 30, 2021 ,
a decrease of approximately $2.0 million . The decrease was due to the
termination of the TENACITY trial and winding down of the ACCURACY trial.
The following table summarizes our research and development expenses by product
candidate or development program for the three and six months ended June 30,
2022 and 2021:
Three Months Ended Six Months Ended
June 30, June 30, June 30, June 30,
2022 2021 2022 2021
($ in thousands)
(Unaudited)
Program-Specific Costs:
AL 101 - - - -
ACC 801 3,680 1,763 7,936
TNBC(1) 1,200 2,533 2,534 3,960
General Expenses 474 263 1,176 803
AL 102
General Expenses 61 10 180 24
Desmoid 3,044 1,635 7,430 2,323
$ 13,083 $ 15,046
(1) As part of our efforts to focus our resources on the more advanced programs
and studies including the RINGSIDE study in desmoid tumors and the ACCURACY
study for ACC, we elected to discontinue the TENACITY trial, which was
evaluating AL101 as a monotherapy in an open-label Phase 2 clinical trial for
the treatment of patients with Notch-activated R/M TNBC.
We expect our research and development expenses to increase for the foreseeable
future as we continue to invest in research and development activities related
to developing our product candidates, including investments in manufacturing, as
our programs advance into later stages of development and as we conduct
additional clinical trials.
Three Months Ended June 30, Six Months Ended June 30,
$ % $ %
2022 2021 Change Change 2022 2021 Change Change
($ in thousands)
(Unaudited)
General and Administrative 2,260 2,536 (276 ) (11 )% 4,701 4,839 (138 ) (3 )%
General and administrative expenses were$2.3 million for the three months endedJune 30, 2022 compared to$2.5 million for the three months endedJune 30, 2021 , a decrease of$0.3 million . General and administrative expenses were$4.7 million for the six months endedJune 30, 2022 compared to$4.8 million for the six months endedJune 30, 2021 , a decrease of$0.1 million . Financial Loss, net Financial loss, net was$156 thousand for the three months endedJune 30, 2022 compared to the financial income, net of$22 thousand for the three months endedJune 30, 2021 . Financial loss, net was$140 thousand for the six months endedJune 30, 2022 compared to the financial income, net of$114 thousand for the same period in 2021. 16
Liquidity and Capital Resources
Sources of Liquidity Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations. Our net losses were approximately$8.2 million and$ 18.2 million for the three and six months endedJune 30, 2022 , respectively. As ofJune 30, 2022 , we had an accumulated deficit of$129.4 million . OnMay 12, 2020 , we completed the sale of shares of our common stock in our IPO. In connection with the IPO, we issued and sold 3,940,689 shares of common stock, including 274,022 shares associated with the partial exercise onJune 4, 2020 of the underwriters' option to purchase additional shares, at a price to the public of$15.00 per share, resulting in net proceeds to us of approximately$52.2 million after deducting underwriting discounts and commissions and estimated offering expenses payable by us. All shares issued and sold were registered pursuant to a registration statement on Form S-1 (File No. 333-236942), as amended, declared effective by theSEC , onMay 7, 2020 (the "IPO Registration Statement").
OnFebruary 19, 2021 , we entered into a Securities Purchase Agreement (the "2021 Purchase Agreement") with the purchasers named therein (the "Investors"). Pursuant to the 2021 Purchase Agreement, we agreed to sell (i) an aggregate of 333,333 shares of our common stock (the "Private Placement Shares"), par value$0.01 per share, together with warrants to purchase an aggregate of 116,666 shares of our common stock with an exercise price of$18.10 per share (the "Common Warrants"), for an aggregate purchase price of$4,999,995.00 and (ii) pre-funded warrants to purchase an aggregate of 1,333,333 shares of our common stock with an exercise price of$0.01 per share (the "Pre-Funded Warrants" and collectively with the Common Warrants, the "Private Placement Warrants"), together with an aggregate of 466,666 Common Warrants, for an aggregate purchase price of$19,986,661.67 (collectively, the "Private Placement"). The Private Placement closed onFebruary 23, 2021 . InJune 2021 , we entered into an Open Market Sales Agreement, or the Sales Agreement, withJefferies LLC , or Jefferies, as sales agent, pursuant to which we may, from time to time, issue and sell common stock with an aggregate value of up to$200.0 million in "at-the-market" offerings (the "ATM"), under our registration statement on Form S-3 (File No. 333-256792) filed with theSEC onJune 4, 2021 (the "ATM Registration Statement"). Sales of common stock, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an "at the market offering" as defined in Rule 415(a) of the Securities Act, including sales made directly through The Nasdaq Global Market or on any other existing trading market for our common stock. Pursuant to the Sales Agreement, during the year endedDecember 31, 2021 , we sold a total of 827,094 shares of common stock for total gross proceeds of approximately$10.4 million . We did not sell any shares of common stock under the Sales Agreement in the six months endedJune 30, 2022 . Subsequent toJune 30, 2022 , we sold a total of 263,875 shares of common stock for total gross proceeds of approximately$419 thousand . The exercise price and the number of shares of common stock issuable upon exercise of each Private Placement Warrant are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock. In addition, in certain circumstances, upon a fundamental transaction, a holder of Common Warrants will be entitled to receive, upon exercise of the Common Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Private Placement Warrants immediately prior to the fundamental transaction. The Pre-Funded Warrants will be automatically exercised on cashless basis upon the occurrence of a fundamental transaction. Each Common Warrant is exercisable from the date of issuance and has a term of three years and each Pre-Funded Warrant is exercisable from the date of issuance and has a term of ten years. Pursuant to the 2021 Purchase Agreement, we registered the Private Placement Shares and Private Placement Warrants for resale by the Investors on a registration statement on Form S-3 (the "Private Placement Registration Statement").
As of
17
Cash Flows
The following table summarizes our cash flow for the six months ended June 30,
2022 and 2021:
Six Months Ended
June 30,
2022 2021
($ in thousands)
(Unaudited)
Cash Flows provided by (used in):
Operating Activities (17,007 ) (21,197 )
Investing Activities - (3 )
Financing Activities 44 23,583Net increase (decrease) in cash and cash equivalents and short-term restricted bank deposits
(16,963 ) 2,383
Operating Activities
Net cash used in operating activities during the six months endedJune 30, 2022 of approximately$17.0 million was primarily attributable to our net loss of$18.2 million , which was partially offset by stock- based compensation of$1.4 million .
Net cash used in operating activities during the six months endedJune 30, 2021 of$21.2 million was primarily attributable to our net loss of$20.4 million , adjusted for non-cash expenses of$0.8 million . Investing Activities We did not have any cash provided by investing activities during the six months endedJune 30, 2022 . Net cash used by investing activities of$3 thousand during the six months endedJune 30, 2021 was primarily attributable to the purchase of property and equipment. Financing Activities
Net cash provided by financing activities during the six months ended
Net cash provided by financing activities during the six months endedJune 30, 2021 of$ 23.6 million was primarily attributable to the Private Placement,
net of issuance costs. Funding Requirements We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development for, initiate later-stage clinical trials for, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. As ofJune 30, 2022 , we had cash and cash equivalents and restricted bank deposits equivalents of$20.4 million . We evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the audited consolidated financial statements are issued. Due to the uncertainty in securing additional funding, and the insufficient amount of cash and cash equivalent resources atJune 30, 2022 , we have concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date of the filing of this Report on Form 10-Q. Our future capital requirements will depend on many factors, including: ? the costs of conducting future clinical trials of AL101 and AL102; ? the cost of manufacturing additional material for future clinical trials of AL101 and AL102; 18 ? the scope, progress, results and costs of discovery, preclinical
development, laboratory testing and clinical trials for other potential
product candidates we may develop or acquire, if any;
? the costs, timing and outcome of regulatory review of our product candidates;
? the achievement of milestones or occurrence of other developments that
trigger payments under any current or future license, collaboration or
other agreements;
? the costs and timing of future commercialization activities, including
product sales, marketing, manufacturing and distribution, for any of our
product candidates for which we receive marketing approval;
? the amount of revenue, if any, received from commercial sales of ourproduct candidates, should any of our product candidates receive marketing
approval;
? the costs of preparing, filing and prosecuting patent applications,obtaining, maintaining, protecting and enforcing our intellectual property
rights and defending intellectual property-related claims;
? the severity, duration and impact of the COVID-19 pandemic, which may
adversely impact our business and clinical trials;
? our headcount growth and associated costs as we expand our business
operations and our research and development activities; and
? the costs of operating as a public company.
Conducting preclinical testing and clinical trials is a time-consuming,
expensive and uncertain process that takes years to complete, and we may never
generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our product candidates, if approved, may not
achieve commercial success. Our commercial revenues, if any, will be derived
from sales of products that we do not expect to be commercially available for
many years, if at all. Accordingly, we will need to continue to rely on
additional financing to achieve our business objectives. Adequate additional
financing may not be available to us on acceptable terms, or at all.
Until such time, if ever, as we can generate substantial product revenues, we
expect to finance our cash needs through a combination of equity offerings, debt
financings, collaborations, strategic alliances and licensing arrangements. We
do not have any committed external source of funds. To the extent that we raise
additional capital through the sale of equity or convertible debt securities,
your ownership interests may be diluted, and the terms of these securities may
include liquidation or other preferences that could adversely affect your rights
as a common stockholder. Any debt financing, if available, may involve
agreements that include restrictive covenants that limit our ability to take
specific actions, such as incurring additional debt, making capital expenditures
or declaring dividends, that could adversely impact our ability to conductour business.
If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, such as our former agreement with Novartis, we may have to relinquish valuable rights to our technologies, intellectual property, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favourable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
On
Contractual Obligations
There have been no material changes to our contractual obligations from those
described in our Annual Report on Form 10-K for the year ended
19
Critical Accounting Policies
Our management's discussion and analysis of financial condition and results of
operations is based on our unaudited condensed consolidated financial
statements, which have been prepared in accordance with accounting principles
generally accepted in the United States , or GAAP. The preparation of these
financial statements requires us to make estimates and judgments that affect the
reported amounts of assets, liabilities and expenses and the disclosure of
contingent assets and liabilities in our consolidated financial statements
during the reporting periods. These items are monitored and analyzed by us for
changes in facts and circumstances, and material changes in these estimates
could occur in the future. We base our estimates on historical experience, known
trends and events, and on various other factors that we believe are reasonable
under the circumstances, the results of which form the basis for making
judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Changes in estimates are reflected in
reported results for the period in which they become known. Actual results may
differ materially from these estimates under different assumptions or
conditions.
There have been no significant changes in our critical accounting policies as
discussed in our Form 10-K, except as described in Note 1 to the unaudited
condensed consolidated financial statements included elsewhere in this Quarterly
Report on Form 10-Q.
Emerging Growth Company Status
The Jumpstart Our Business Start-ups Act of 2012, or the JOBS Act, permits an "emerging growth company" such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our IPO, orDecember 31, 2025 , (b) in which we have total annual gross revenues of$1.07 billion or more, or (c) in which we are deemed to be a large accelerated filer under the rules of theSEC , which means the market value of our outstanding common stock held by non-affiliates exceeds$700 million as of last business day of our most recently completed second fiscal quarter, and (2) the date on which we have issued more than$1.0 billion in nonconvertible debt during the previous three years.
© Edgar Online, source
